Education
About Us
Working with TipRanks
Follow Us
Verrica Pharmaceuticals (VRCA)
NASDAQ:VRCA
VRCA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.38 - $11.41
Previous CloseN/A
Volume115.12K
Average Volume (3M)564.86K
Market Cap
$42.48M
Enterprise Value$92.02M
Total Cash (Recent Filing)-$527.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.51
Next Earnings
May 07, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding91,779,990
10 Day Avg. Volume584,812
30 Day Avg. Volume564,862
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.77
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap2.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit16.11
Enterprise Value/Ebitda-1.40
Forecast
1Y Price Target
$3.50Price Target Upside629.17% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
Verrica Pharmaceuticals News
PremiumCompany Announcements
Verrica Pharmaceuticals Appoints Dr. Corcoran as Director
PremiumCompany Announcements
Verrica Pharmaceuticals’ Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Verrica Pharmaceuticals Reports Positive Q4 2024 Results---
Bulls Say, Bears Say
Bulls Say
Commercial StrategyManagement is implementing a new commercial strategy focusing on key territories with high molluscum prevalence and strong insurance coverage.
Inventory ManagementEncouragingly, management highlighted inventory stabilization in Q4, ahead of expectations, with demand driven sales beginning in Q1.
Product DemandThere appears to be increasing demand in Q4, with 8,654 applicators dispensed (+12% Q/Q) vs. 7,706 in Q3.
Bears Say
Financial ConcernsThere remains a significant overhang for financing operations and debt pay-down.
Liquidity ChallengesThe Neutral rating is maintained due to concerns about precarious liquidity in a challenging market, pending more clarity on Verrica's strategy to achieve breakeven.
Revenue UncertaintyIt's unclear if the higher volume of dispensed applicator units will result in 4Q24 sales since the company reported negative net product revenues for 3Q.
---
Ownership Overview
45.13% Insiders
2.68% Mutual Funds
25.61% Other Institutional Investors
23.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRCA FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was $0.38 and its highest was $11.41 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Verrica Pharmaceuticals’s market cap is $42.48M.
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is May 07, 2025 which is in 24 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on Mar 11, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.01.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -0.13.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 91,779,990 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went down -7.692%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Currently, no hedge funds are holding shares in VRCA
---
Verrica Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.50 (629.17% Upside)
$3.50 (629.17% Upside)
Blogger Sentiment
Bullish
VRCA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.85%
12-Months-Change
Fundamentals
Return on Equity
-1546.58%
Trailing 12-Months
Asset Growth
-33.06%
Trailing 12-Months
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
---
VRCA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in Verrica Pharmaceuticals' financial position, YCANTH sales growth, and clinical pipeline advancements. However, challenges such as obsolete inventory costs, suboptimal revenue figures, and financial covenant concerns were also noted. Overall, the positive developments in fundraising, sales growth, and clinical progress were prominent.Read More>---
VRCA Stock 12 Month Forecast
Average Price Target
$3.50
▲(629.17% Upside)
Technical Analysis
Cutera
―
Fresh Tracks Therapeutics
―
VYNE Therapeutics
―
Evolus
―
Journey Medical Corp
―
Best Analysts Covering VRCA
1 Year
---